Literature DB >> 25113943

Static and rotational intensity modulated techniques for head-neck cancer radiotherapy: a planning comparison.

Sara Broggi1, Lucia Perna2, Francesco Bonsignore3, Giuseppe Rinaldin2, Claudio Fiorino2, Anna Chiara4, Cristina Frigerio3, Ivana Butti3, Giulia Sangalli3, Italo Dell'Oca4, Nadia Di Muzio4, Giovanni Mauro Cattaneo2, Fausto Declich3.   

Abstract

PURPOSE: To compare helical Tomotherapy (HT), two volumetric-modulated arc techniques and conventional fixed-field intensity modulated techniques (S-IMRT) for head-neck (HN) cancers. METHODS AND MATERIALS: Eighteen HN patients were considered. Four treatment plans were generated for each patient: HT, S-IMRT optimised with Eclipse treatment planning system and two volumetric techniques using Elekta-Oncentra approach (VMAT) and Varian-RapidArc (RA), using two full arcs. All techniques were optimised to simultaneously deliver 66Gy to PTV1 (GTV and enlarged nodes) and 54Gy to PTV2 (subclinical and electively treated nodes). Comparisons were assessed on several dosimetric parameters and, secondarily, on planned MUs and delivery time.
RESULTS: Concerning PTV coverage, significantly better results were found for HT and RA. HT significantly improved the target coverage both compared to S-IMRT and VMAT. No significant differences were found between S-IMRT and volumetric techniques in terms of dose homogeneity. For OARs, all the techniques were able to satisfy all hard constraints; significantly better results were found for HT, especially in the intermediate dose range (15-30 Gy). S-IMRT reached a significantly better OARs sparing with respect to VMAT and RA. No significant differences were found for body mean dose, excepting higher values of V5-V10 for HT. A reduction of planned MUs and delivery treatment time was found with volumetric techniques.
CONCLUSIONS: The objectives of satisfying target coverage and sparing of critical structures were reached with all techniques. S-IMRT techniques were found more advantageous compared to RA and VMAT for OARs sparing. HT reached the best overall treatment plan quality.
Copyright © 2014 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Dosimetrical comparison; Head and neck cancer; IMRT; Volumetric arc techniques

Mesh:

Year:  2014        PMID: 25113943     DOI: 10.1016/j.ejmp.2014.07.001

Source DB:  PubMed          Journal:  Phys Med        ISSN: 1120-1797            Impact factor:   2.685


  10 in total

1.  Volumetric modulated arc therapy (VMAT) and simultaneous integrated boost in head-and-neck cancer: is there a place for critical swallowing structures dose sparing?

Authors:  Savino Cilla; Francesco Deodato; Gabriella Macchia; Cinzia Digesù; Anna Ianiro; Angelo Piermattei; Vincenzo Valentini; Alessio G Morganti
Journal:  Br J Radiol       Date:  2016-01-05       Impact factor: 3.039

2.  Clinical outcomes of concurrent chemoradiotherapy with volumetric modulated arc therapy in patients with locally advanced nasopharyngeal carcinoma.

Authors:  Nobuki Imano; Yuji Murakami; Takeo Nakashima; Yuki Takeuchi; Ippei Takahashi; Yoshiko Doi; Ikuno Nishibuchi; Tomoki Kimura; Koichi Wadasaki; Tsutomu Ueda; Katsuhiro Hirakawa; Yasushi Nagata
Journal:  Jpn J Radiol       Date:  2017-09-08       Impact factor: 2.374

3.  Is volumetric modulated arc therapy with constant dose rate a valid option in radiation therapy for head and neck cancer patients?

Authors:  Annamaria Didona; Valentina Lancellotta; Claudio Zucchetti; Bianca Moira Panizza; Alessandro Frattegiani; Martina Iacco; Anna Concetta Di Pilato; Simonetta Saldi; Cynthia Aristei
Journal:  Rep Pract Oncol Radiother       Date:  2018-03-19

4.  Radiation dose escalation based on FDG-PET driven dose painting by numbers in oropharyngeal squamous cell carcinoma: a dosimetric comparison between TomoTherapy-HA and RapidArc.

Authors:  Sarah Differding; Edmond Sterpin; Nicolas Hermand; Bianca Vanstraelen; Sandra Nuyts; Nathalie de Patoul; Jean-Marc Denis; John Aldo Lee; Vincent Grégoire
Journal:  Radiat Oncol       Date:  2017-03-23       Impact factor: 3.481

5.  The Outcome of the First 100 Nasopharyngeal Cancer Patients in Thailand Treated by Helical Tomotherapy.

Authors:  Imjai Chitapanarux; Wannapha Nobnop; Patumrat Sripan; Ausareeya Chumachote; Ekkasit Tharavichitkul; Somvilai Chakrabandhu; Pitchayaponne Klunklin; Wimrak Onchan; Bongkot Jia-Mahasap; Suwapim Janlaor; Patcharawadee Kayan; Patrinee Traisathit; Dirk Van Gestel
Journal:  Radiol Oncol       Date:  2017-04-21       Impact factor: 2.991

6.  A Model-Based Method for Assessment of Salivary Gland and Planning Target Volume Dosimetry in Volumetric-Modulated Arc Therapy Planning on Head-and-Neck Cancer.

Authors:  Honglai Zhang; Yijian Cao; Jeffrey Antone; Adam C Riegel; Maged Ghaly; Louis Potters; Abolghassem Jamshidi
Journal:  J Med Phys       Date:  2019 Jul-Sep

7.  Skin dose calculation during radiotherapy of head and neck cancer using deformable image registration of planning and mega-voltage computed tomography scans.

Authors:  Marco Branchini; Sara Broggi; Italo Dell'Oca; Giovanni Mauro Cattaneo; Riccardo Calandrino; Nadia Gisella Di Muzio; Claudio Fiorino
Journal:  Phys Imaging Radiat Oncol       Date:  2018-12-01

Review 8.  Dosimetric justification for the use of volumetric modulated arc therapy in head and neck cancer-A systematic review of the literature.

Authors:  Nikolett Buciuman; Loredana G Marcu
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-08-16

9.  A Practical Method to Optimize Quality Assurance Results of Arc Therapy Plans in Beam Modeling.

Authors:  Jinyu Xue; Hesheng Wang; David Barbee; Matthew Schmidt; Indra J Das
Journal:  J Med Phys       Date:  2018 Apr-Jun

10.  Dosimetric Comparisons of Volumetric Modulated Arc Therapy and Tomotherapy for Early T-Stage Nasopharyngeal Carcinoma.

Authors:  Shan Li; Qin Zhou; Liang-Fang Shen; Huan Li; Zhan-Zhan Li; Zhen Yang; Ming-Jun Lei; Xiao-Yu Yang; Zi-Jian Zhang; Yong-Mei Hu; Ze-Fu Jin; Gui Liu; Zhi-Ping Lv; Xin-Qiong Huang
Journal:  Biomed Res Int       Date:  2018-06-04       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.